Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary

Kura Oncology, Inc. (KURA) will report Q4 and full year 2023 financial results on Feb 27, 2024. The company aims to advance precision medicines for cancer treatment with a webcast and conference call scheduled for the same day.

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2023 financial results after the close of U.S. financial markets on Tuesday, February 27, 2024. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing (888) 886-7786 for domestic callers and (416) 764-8658 for international callers. A live webcast and archived replay of the event will be available here or online from the investor relations section of the company website at www.kuraoncology.com.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute leukemia patients with high unmet need. Kura is currently enrolling patients in a Phase 2 registration-directed trial of ziftomenib in NPM1-mutant relapsed/refractory acute myeloid leukemia (AML) (KOMET-001). The Company is also conducting a series of studies to evaluate ziftomenib in combination with current standards of care, beginning with venetoclax/azacitidine and cytarabine/daunorubicin (7+3) in NPM1-mutant and KMT2A-rearranged newly diagnosed and relapsed/refractory AML (KOMET-007). Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as monotherapy and in combination with cabozantinib in clear cell renal cell carcinoma and with adagrasib in KRAS^G12C-mutated non-small cell lung cancer (FIT-001). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.

Contacts

Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com

Media:
Alexandra Weingarten
Associate Director, Investor Relations &
Corporate Communications
(858) 500-8822
alexandra@kuraoncology.com

FAQ

When will Kura Oncology report its Q4 and full year 2023 financial results?

Kura Oncology will report its Q4 and full year 2023 financial results after the close of U.S. financial markets on Tuesday, February 27, 2024.

What is the ticker symbol for Kura Oncology?

The ticker symbol for Kura Oncology is KURA.

What time will the webcast and conference call for Kura Oncology's financial results take place on Feb 27, 2024?

The webcast and conference call for Kura Oncology's financial results will take place at 4:30 p.m. ET / 1:30 p.m. PT on February 27, 2024.

How can domestic callers access the live call for Kura Oncology's financial results?

Domestic callers can access the live call for Kura Oncology's financial results by dialing (888) 886-7786.

Where can the archived replay of Kura Oncology's financial results event be found?

The archived replay of Kura Oncology's financial results event can be found online from the investor relations section of the company website at www.kuraoncology.com.